Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 03/31/22 → 12/31/25 |
Funding
- Boehringer Ingelheim Pharmaceutical: $35,462.40
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26-week treatment period in patients with schizophrenia (CONNEX-1)
- Dubovsky, Steven (PI)
- Smith, Beth (PI)
Project: Research